BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

300.80 +0.99 (+0.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Price and Volume

Volume	160,886
Open	301.60
Bid (Size)	296.00 (400)
Ask (Size)	305.73 (40)
Prev. Close	299.81
Today's Range	297.53 - 301.60
52wk Range	218.31 - 385.22
Shares Outstanding	1,211,067,023
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half ↗

March 19, 2026

Futu Holdings delivers digital brokerage and wealth management solutions to retail and institutional clients across Asia and global markets.

Via The Motley Fool

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini's SEPA Screen with Strong Technicals and High Growth Momentum ↗

February 26, 2026

Via Chartmill

Performance

YTD	-3.3%	-3.3%
1 Month	+6.1%	+6.1%
3 Month	-11.4%	-11.4%
6 Month	-3.2%	-3.2%
1 Year	+17.4%	+17.4%

More News

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

February 26, 2026

From BeOne Medicines Ltd.

Via Business Wire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗

January 21, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term ↗

February 21, 2026

Via The Motley Fool

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model ↗

February 20, 2026

Via The Motley Fool

BeOne Medicines to Present at Upcoming Investor Conferences

February 17, 2026

From BeOne Medicines Ltd.

Via Business Wire

Prediction: These 3 Stocks Will Crush the Market in 2026 ↗

February 16, 2026

Via The Motley Fool

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

February 11, 2026

From BeOne Medicines Ltd.

Via Business Wire

3 Stocks to Buy in February ↗

February 02, 2026

Via The Motley Fool

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From BeOne Medicines Ltd.

Via Business Wire

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

January 06, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

December 18, 2025

From BeOne Medicines Ltd.

Via Business Wire

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

December 08, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗

December 07, 2025

Via Benzinga

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

December 07, 2025

From BeOne Medicines Ltd.

Via Business Wire

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

November 26, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

November 20, 2025

From BeOne Medicines Ltd.

Via Business Wire

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Via Benzinga

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

From BeOne Medicines Ltd.

Via Business Wire

Frequently Asked Questions

Is BeOne Medicines Ltd. - American Depositary Shares publicly traded?

Yes, BeOne Medicines Ltd. - American Depositary Shares is publicly traded.

What exchange does BeOne Medicines Ltd. - American Depositary Shares trade on?

BeOne Medicines Ltd. - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for BeOne Medicines Ltd. - American Depositary Shares?

The ticker symbol for BeOne Medicines Ltd. - American Depositary Shares is ONC on the Nasdaq Stock Market

What is the current price of BeOne Medicines Ltd. - American Depositary Shares?

The current price of BeOne Medicines Ltd. - American Depositary Shares is 300.80

When was BeOne Medicines Ltd. - American Depositary Shares last traded?

The last trade of BeOne Medicines Ltd. - American Depositary Shares was at 04/24/26 04:00 PM ET

What is the market capitalization of BeOne Medicines Ltd. - American Depositary Shares?

The market capitalization of BeOne Medicines Ltd. - American Depositary Shares is 364.29B

How many shares of BeOne Medicines Ltd. - American Depositary Shares are outstanding?

BeOne Medicines Ltd. - American Depositary Shares has 364B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.